ENALAPRIL AFTER ANTHRACYCLINE CARDIOTOXICITY

蒽环类药物心脏毒性后依那普利

• 批准号: 6305961
• 负责人: MONIKA RUTKOWSKI
• 金额: $ 2.1万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6305961
• 关键词: anthracyclines; cardiotoxin; clinical research; clinical trials; drug adverse effect; drug screening /evaluation; enalapril; heart disorder; heart disorder chemotherapy; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; pediatric neoplasm /cancer

The primary objective of this randomized, double-blinded placebo controlled trial is to determine whether the long-term administration of enalapril, an angiotensin converting enzyme inhibitor, will decrease the rate of anthracycline-induced cardiac dysfunction in patients without overt congestive heart failure. All patients must have documented cardiac abnormalities secondary to anthrocyclines used for treating pediatric malignancies and have received therapy more than two years ago.

本随机双盲安慰剂对照试验的主要目的是确定长期给予血管紧张素转换酶抑制剂依那普利是否会降低无明显充血性心力衰竭患者蒽环类药物诱导的心功能不全的发生率。 所有患者必须有记录的心脏异常继发于用于治疗儿科恶性肿瘤的蒽环类药物，并已接受治疗超过两年。